Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07299071

Randomized Controlled Trial Evaluating the Efficacy of CAD in Screening Colonoscopy to Reduce the Risk of Advanced Adenoma at 3 Years

Led by University Hospital, Bordeaux · Updated on 2026-03-16

592

Participants Needed

13

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying the use of computer-aided diagnosis (CAD) systems during colonoscopy to detect colorectal lesions and potentially reduce the risk of advanced adenomas or interval cancers over three years. The study addresses the challenge of missed lesions during colonoscopy and evaluates whether CAD can improve cancer prevention in patients undergoing colorectal cancer screening. Participants will be randomly assigned during their screening colonoscopy to receive either a standard colonoscopy or a colonoscopy assisted by a CAD system (CAD EYE or GENIUS). After the initial procedure, patients will have a follow-up consultation one month later and then a scheduled colonoscopy at three years. For those at higher risk, the three-year follow-up colonoscopy will use the CAD system again, performed by a different investigator who is unaware of previous results. During the study, researchers will monitor outcomes such as the presence of advanced adenomas at 36 months, the number of adenomas detected, and the sensitivity and specificity of the CAD system. They will also evaluate the costs associated with CAD versus standard colonoscopy. Data from routine care colonoscopies will be collected for low-risk patients. The total participation duration extends to at least three years, including follow-up visits and repeat colonoscopies as scheduled.

CONDITIONS

Brief Title

Efficacy of CAD in Screening Colonoscopy to Reduce the Risk of Advanced Adenoma at 3 Years.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients over 18 years of age with indication for colonoscopy as part of a screening program, after a positive immunological (FIT) test, and/or for personal or family history of colorectal cancer and/or personal history of colonic adenomas
  • Written informed consent signed
  • Patients covered by a health-care insurance
Not Eligible

You will not qualify if you...

  • Failed complete colonoscopy, defined by the absence of cecal intubation and/or the absence of terminal ileum cauterization
  • Inadequate bowel preparation (Boston bowel preparation score < 6, and/or least at one part of colon with score 41)
  • An infiltrative tumor was diagnosed during colonoscope insertion time, not accessible to endoscopic resection and likely to require surgical management
  • Patient under guardianship or protection
  • Pregnant women
  • Not fluent in French or illiterate
  • Personal history of inflammatory bowel disease
  • Personal history of genetic predisposition of CRC
  • Personal history of colonic surgery

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 pre-colonoscopy consultation visit

Diagnostic Evaluation

Duration - Day 0

Participants undergo a screening colonoscopy and are randomized to receive either standard colonoscopy or colonoscopy with CADe.

1 colonoscopy visit (in-person, randomized after confirmed cecal intubation and bowel preparation)

Follow-up

Duration - 1 month

Participants have a follow-up consultation one month after colonoscopy to receive histological results.

1 follow-up consultation visit

Long-term Monitoring

Duration - 3 years

Participants are monitored over 3 years, including a new control colonoscopy for high-risk patients and routine care follow-up for low-risk patients.

1 control colonoscopy visit for high-risk patients and routine follow-up for low-risk patients

Trial Site Locations

Total: 13 locations

1

CH de la Côte Basque

Bayonne, France, 64100

Not Yet Recruiting

2

CHU Brest la Cavale Blanche

Brest, France, 29200

Not Yet Recruiting

3

Clinique Paris Bercy

Charenton-le-Pont, France, 94220

Not Yet Recruiting

4

CHU de Limoges

Limoges, France, 87042

Not Yet Recruiting

5

Institut Paoli Calmettes

Marseille, France, 13009

Not Yet Recruiting

6

Clinique Jules Verne

Nantes, France, 44300

Not Yet Recruiting

7

CHU Nîmes

Nîmes, France, 30029

Not Yet Recruiting

8

APHP - Hôpital Saint Antoine

Paris, France, 75012

Not Yet Recruiting

9

Aphp-Hegp

Paris, France, 75015

Not Yet Recruiting

10

CHU Bordeaux - Hôpital Haut Lévêque

Pessac, France, 33604

Actively Recruiting

11

CHU de Rennes

Rennes, France, 35000

Not Yet Recruiting

12

Clinique Pasteur

Toulouse, France, 31076

Not Yet Recruiting

13

CHRU de Nancy - Hôpital Brabois Adultes

Vandœuvre-lès-Nancy, France, 54511

Not Yet Recruiting

Loading map...

Research Team

A

Arthur BERGER, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

DIAGNOSTIC

Number of Arms

2

Similar Trials

Phase 1/2 Trial of BLU-924 (SAR449336) Evaluating Safety, To...

Advanced Solid Tumor

Actively Recruiting

1 location

A Multicenter, Double Blinded Randomized Controlled Trial of...

Colorectal Neoplasms

Actively Recruiting

2 locations

A Phase I/II Trial of UCB4594 to Assess Safety, Pharmacokine...

Advanced Solid Tumours

Actively Recruiting

4 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here